Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/10/2005WO2005020959A2 Novel drug compositions and dosage forms of topiramate
03/10/2005WO2005020958A2 Aerosol delivery of curcumin
03/10/2005WO2005020957A2 Stepwise delivery of topiramate over prolonged period of time
03/10/2005WO2005020955A1 Compositions for preventing scars and fibrosis after injury or surgery
03/10/2005WO2005020954A2 Proton pump inhibitor formulations, and methods of preparing and using such formulations
03/10/2005WO2005020935A2 Method and composition of administering radioprotectants
03/10/2005WO2005020932A2 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
03/10/2005WO2005020929A2 Sustained release dosage forms of ziprasidone
03/10/2005WO2005020928A2 Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
03/10/2005WO2005020926A2 Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
03/10/2005WO2005020923A2 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
03/10/2005WO2005020921A2 C-kit modulators and methods of use
03/10/2005WO2005020920A2 Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
03/10/2005WO2005020917A2 Ophthalmic compositions for treating ocular hypertension
03/10/2005WO2005020915A2 Silver dihydrogen citrate compositions comprising a second antimicrobial agent
03/10/2005WO2005020914A2 Pyridomorphinans, pyridazinomorphinans and use thereof
03/10/2005WO2005020913A2 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
03/10/2005WO2005020911A2 Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same
03/10/2005WO2005020910A2 Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
03/10/2005WO2005020909A2 Cellular depolarization and regulation of matrix metalloproteinases
03/10/2005WO2005020908A2 Selective inhibitors of stat-3 activation and uses thereof
03/10/2005WO2005020906A2 Intranasal opioid compositions
03/10/2005WO2005020904A2 Oral neurotherapeutic cefazolin compositions
03/10/2005WO2005020903A2 Methods of improving the safety of zonisamide therapy
03/10/2005WO2005020901A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020900A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020897A2 Compositions and methods for the treatment of disease associated with trp-p8 expression
03/10/2005WO2005020896A2 N,n-dihalogenated amino acids and derivatives
03/10/2005WO2005020895A2 Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
03/10/2005WO2005020887A2 Method for treatment of severe acute respiratory syndrome
03/10/2005WO2005020885A2 Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
03/10/2005WO2005020882A2 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005WO2005020881A2 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases
03/10/2005WO2005020880A2 Methods for the treatment of endometriosis
03/10/2005WO2005020879A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005WO2005020877A2 Use of biotin or a biotin derivative for lightening skin and treating age spots
03/10/2005WO2005020876A2 Pharmaceutical composition, method of manufacturing and therapeutic use thereof
03/10/2005WO2005020862A1 Crosslinking reagent for treating vertebral disc disorders
03/10/2005WO2005020840A2 Composition and method for marking procaine penicillin
03/10/2005WO2005020709A1 Food product providing sustained blood levels of exogenous substances
03/10/2005WO2005020684A2 Control of protozoa and protozoan cysts that harbor legionella
03/10/2005WO2005011583A3 Treatment of allergic rhinitis and asthma
03/10/2005WO2005011572A3 Combination of drugs for the treatment of neoplasms
03/10/2005WO2005009421A8 The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
03/10/2005WO2005007241A8 Parasiticidal composition
03/10/2005WO2005007192A3 Cytoprotection through the use of hif hydroxylase inhibitors
03/10/2005WO2005004858A8 Combinations of vasoactive agents, their use in the pharmaceutical and cosmetic field, and formulations containing them
03/10/2005WO2005003065A3 Sulfonamide substituted imidazoquinolines
03/10/2005WO2005000795A3 Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
03/10/2005WO2005000284A3 Diaryl ureas for diseases mediated by pdgfr
03/10/2005WO2005000267A3 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
03/10/2005WO2005000109A3 Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids
03/10/2005WO2004112793B1 Guanidino-substituted quinazolinone compounds as mc4-r agonists
03/10/2005WO2004112780B1 Metronidazole-based green tinted topical pharmaceutical composition
03/10/2005WO2004112730A3 Method and compositions for treating tumors
03/10/2005WO2004110380A3 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
03/10/2005WO2004110360A9 Proteoglycan degrading mutants for treatment of cns
03/10/2005WO2004108162A3 Controlled release pharmaceutical composition
03/10/2005WO2004108139A3 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
03/10/2005WO2004108062A3 Prophylaxis and/or treatment of portal hypertension
03/10/2005WO2004105731A8 Nasal formulations including a topical decongestant and a topical corticosteroid and their use in treatment of obstructive sleep apnea
03/10/2005WO2004105690A3 Treatment of chronic pain associated with drug or radiation therapy
03/10/2005WO2004105687A3 Antimicrobial quaternary ammonium organosilane coatings
03/10/2005WO2004105492A8 Aqueous compositions for disinfection and/or sterilization
03/10/2005WO2004103278A3 Acyl sulfonamides as inhibitors of hiv integrase
03/10/2005WO2004100826A3 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
03/10/2005WO2004098562A3 Controlled release solid dosage nifedipine formulations
03/10/2005WO2004096795A3 C-fms kinase inhibitors
03/10/2005WO2004096225A3 Use of tyrosine kinase inhibitors for treating cerebral ischemia
03/10/2005WO2004096196A3 Treatment of incontinence with 5htc2 agonists
03/10/2005WO2004096128A3 Hiv integrase inhibitors
03/10/2005WO2004093827A3 Phenolic acid salts of gabapentin in solid dosage forms and methods of use
03/10/2005WO2004091497A3 Methods and compositions for increasing the anaerobic working capacity in tissues
03/10/2005WO2004089342A3 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic exipient
03/10/2005WO2004089289A3 Treating or preventing hot flashes using prodrugs of gaba analogs
03/10/2005WO2004087880A3 Compounds and their use to treat diabetes and related disorders
03/10/2005WO2004087673B1 Migrastatin analogs and uses thereof
03/10/2005WO2004082613A3 2,4-diamino-5-[5’-substituted-benzyl] pyrimidines and 2,4-diamino-6-[5’-substituted-benzyl] quinazolines
03/10/2005WO2004082601A3 Method of treating diabetes and diabetes-related disorders
03/10/2005WO2004078172A3 Sod mimic multifunctional compounds for treating inflammatory bowel disease
03/10/2005WO2004071447B1 Substituted azole derivatives as therapeutic agents
03/10/2005WO2004071432A3 Method for treating hypothyroidism
03/10/2005WO2004069236A9 Inhibitor for perioperative blood sugar elevation
03/10/2005WO2004067481A3 Improved jasmine aromachemicals
03/10/2005WO2004056971A3 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
03/10/2005WO2004041802A8 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
03/10/2005WO2004034968A3 Combination therapy for controlling appetites
03/10/2005WO2004012733A9 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
03/10/2005WO2003093409A3 Promoters exhibiting endothelial cell specificity and methods of using same
03/10/2005WO2003092720A8 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
03/10/2005WO2003079987A3 A non-selective cation channel in neural cells and methods for treating brain swelling
03/10/2005WO2003073990A3 Treatment for asthma or allergies
03/10/2005WO2003072046A3 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
03/10/2005WO2003027254A9 15625 receptor, a novel g-protein coupled receptor
03/10/2005WO2002087604A8 Preparations containing a combination of vitamin e and afamin
03/10/2005WO2001066772A9 Heparinase iii and uses thereof
03/10/2005US20050054851 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
03/10/2005US20050054850 E.g., {4-Chloro-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine; congestive heart failure, stroke, antiischemic, -arrhythmia, -arthritis, -diabetic, -inflammatory, -ulcer and hypotensive agents; urogenital, bone, respiratory, cardiovascular and nervous systems disorders
03/10/2005US20050054820 Expression vector comprising nucleotide sequences coding calreticulin/heat shock protein fusion for use as tool in enhancement and induction of major histocompatibility complex immunological response; immunotherapy; tissue targeted therapy
03/10/2005US20050054819 Such as 1-benzylcyclobutyl (1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate for treatment of osteoporosis
1 ... 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 ... 7860